Myomancy ADHD, Dyslexia and Autism

Shire Plc announces first quarter sales growth - Healthcare Digital

Shire Plc announces first quarter sales growth
Healthcare Digital, UK - 2 hours ago
The company announced that its Vyvanse product had achieved a 6.9 percent share of the US attention deficit hyperactivity disorder (ADHD) market. …
Shire posts strong revenue growth, shrugs off Vyvanse fears Pharma Times (subscription)
Shire sees upside to Vyvanse sales forecast Therapeutics Daily (subscription) (press release)
Ahead of the Bell: Shire downgraded by Credit Suisse Houston Chronicle
Bloomberg - Forbes
all 17 news articles

Find Out More:

Books:

April 28th, 2008
ADHD News

Leave a Reply

*Required

Truncated Domes

ADHD Boarding Schools

Pharmaceuticals GMP Procedures

Moving

Child Development

Natural ADHD Treatments



Discuss the topics raised by this article on the Myomancy Forum.

Archives


7422 posts since May 2004

Google Search

Search Myomancy for news and information about ADHD, Dyslexia and Autism including diagnosis techniques, treatments and the science behind them.

Myomancy Treatment Database

A comprehensive list of every type of treatment available for ADHD, Autism and Dyslexia reviewed and rated by people who have tried them is available on the Myomancy Treatment Database. It covers mainstream treatments focusing on Reading as well as those less recognised using Biofeedback, Dietry and Rhythm. There are also treatments that deal with specific issues such as Audiotory, Visual, Balance, Coordination, Memory. Some treatments are provided as special centers whilst others are available via Books, CDs, DVDs or Software.

Read the latest on ADHD, Dyslexia and Autism from Myomancy via RSS 2.0 or use FeedBurner: